See more : Manhattan Scientifics, Inc. (MHTX) Income Statement Analysis – Financial Results
Complete financial analysis of Innovent Biologics, Inc. (IVBXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Innovent Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Pioneer Municipal High Income Opportunities Fund, Inc. (MIO) Income Statement Analysis – Financial Results
- XPhyto Therapeutics Corp. (4XT.DE) Income Statement Analysis – Financial Results
- Zynex, Inc. (ZYXI) Income Statement Analysis – Financial Results
- Westinghouse Air Brake Technologies Corporation (WB2.DE) Income Statement Analysis – Financial Results
- 2CRSI S.A. (AL2SI.PA) Income Statement Analysis – Financial Results
Innovent Biologics, Inc. (IVBXF)
About Innovent Biologics, Inc.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.21B | 4.56B | 4.27B | 3.84B | 1.05B | 9.48M | 18.54M | 32.13M |
| Cost of Revenue | 1.81B | 930.99M | 573.04M | 387.76M | 124.88M | -1.31M | -71.47M | 0.00 |
| Gross Profit | 4.40B | 3.63B | 3.70B | 3.46B | 922.65M | 10.79M | 90.01M | 32.13M |
| Gross Profit Ratio | 70.89% | 79.57% | 86.58% | 89.91% | 88.08% | 113.84% | 485.54% | 100.00% |
| Research & Development | 2.23B | 2.87B | 2.48B | 1.85B | 1.29B | 1.22B | 611.92M | 384.65M |
| General & Administrative | 750.28M | 835.49M | 884.03M | 436.87M | 255.30M | 277.50M | 87.77M | 57.38M |
| Selling & Marketing | 3.10B | 2.59B | 2.73B | 1.34B | 1.19B | 136.01M | 9.94M | 5.03M |
| SG&A | 3.85B | 3.43B | 3.61B | 1.78B | 1.45B | 413.51M | 87.77M | 57.38M |
| Other Expenses | 0.00 | -90.20M | -45.13M | -130.69M | -41.38M | -4.34B | -51.01M | -123.20M |
| Operating Expenses | 5.07B | 6.21B | 6.05B | 3.50B | 2.70B | 1.56B | 643.27M | 413.27M |
| Cost & Expenses | 7.89B | 7.14B | 6.62B | 3.89B | 2.83B | 1.56B | 643.27M | 413.27M |
| Interest Income | 452.84M | 189.54M | 151.76M | 116.10M | 102.70M | 20.68M | 7.98M | 4.54M |
| Interest Expense | 98.62M | 101.70M | 62.46M | 68.35M | 59.49M | 68.97M | 57.23M | 53.80M |
| Depreciation & Amortization | 385.10M | 319.42M | 204.75M | 85.63M | 86.37M | 64.06M | 61.10M | 53.35M |
| EBITDA | -660.68M | -1.75B | -2.37B | -704.74M | -1.57B | -5.74B | -597.72M | -359.92M |
| EBITDA Ratio | -10.65% | -38.51% | -68.11% | -19.11% | -150.52% | -60,586.43% | -3,430.40% | -1,413.33% |
| Operating Income | -1.68B | -2.07B | -3.11B | -820.14M | -1.66B | -1.79B | -750.14M | -461.54M |
| Operating Income Ratio | -27.06% | -45.52% | -72.91% | -21.34% | -158.76% | -18,841.75% | -4,046.48% | -1,436.60% |
| Total Other Income/Expenses | 534.89M | -96.54M | 61.63M | -301.53M | -56.86M | -4.32B | -91.32M | -131.19M |
| Income Before Tax | -1.14B | -2.17B | -3.05B | -858.71M | -1.72B | -5.87B | -716.05M | -544.46M |
| Income Before Tax Ratio | -18.44% | -47.64% | -71.46% | -22.34% | -164.19% | -61,970.90% | -3,862.61% | -1,694.69% |
| Income Tax Expense | -116.50M | 8.80M | 87.04M | 139.71M | 56.86M | 27.48M | -244.37M | -150.97M |
| Net Income | -1.03B | -2.18B | -3.14B | -998.42M | -1.78B | -5.77B | -562.32M | -504.20M |
| Net Income Ratio | -16.56% | -47.83% | -73.50% | -25.97% | -169.62% | -60,899.99% | -3,033.33% | -1,569.40% |
| EPS | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.50 | -0.45 |
| EPS Diluted | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.50 | -0.45 |
| Weighted Avg Shares Out | 1.56B | 1.49B | 1.45B | 1.35B | 1.18B | 334.68M | 1.12B | 1.12B |
| Weighted Avg Shares Out (Dil) | 1.56B | 1.49B | 1.46B | 1.36B | 1.18B | 334.68M | 1.12B | 1.12B |
Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA
Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints
Source: https://incomestatements.info
Category: Stock Reports